Is FSNUF Stock Undervalued?

A comprehensive valuation analysis of Fresenius SE & Co. KGaA (FSNUF) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated June 15, 2026•8 min read•View Full Analysis

Valuation Verdict

→

Fairly Valued

0.0% downside risk

Based on our analysis, Fresenius SE & Co. KGaA appears to be fairly valued at the current price of $0.00.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing FSNUF relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

17.15

Moderate

P/B Ratio

N/A

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: At 17.15x earnings, FSNUF is trading near the typical market average of 15-20x.
P/B Ratio: Book value data not available.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Fresenius SE & Co. KGaA stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$0.00

Fair Value Estimate

N/A

Unable to calculate a reliable fair value estimate due to insufficient financial data or negative cash flows. This is common for early-stage growth companies or those undergoing restructuring.

Investment Conclusion

Bottom Line

Fresenius SE & Co. KGaA (FSNUF) appears fairly valued at $0.00, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Healthcare without significant valuation risk.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.